Poultry immunopotentiator and application thereof

By adding 0.4% to 1.0% w/v echinacea extract and 0.2% to 1.0% w/v vitamin E to the avian influenza vaccine, the immune effect rate and sustained immunity of H9 subtype avian influenza vaccine were solved. The problem of insufficient period has achieved rapid production of high-level antibodies and long-term immune protection effects.

CN118948914APending Publication Date: 2024-11-15TECON BIOPHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410904684.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-08
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing H9 subtype avian influenza vaccine has a slow onset of immunity, insufficient immune effect, and the duration of immunity cannot meet actual needs, resulting in a high infection rate of avian herds and huge economic losses.

Method used

Immune enhancer containing 0.4% to 1.0% w/v echinacea extract and 0.2% to 1.0% w/v vitamin E is used, and it works together with the adjuvant to stimulate the body to quickly produce high-level antibodies and prolong the duration of immunity. In the vaccine for poultry.

Benefits of technology

It effectively improves the efficiency of vaccine use, promotes the body to produce high-level antibodies quickly, and significantly prolongs the duration of immunity, significantly improving the immune protection effect of the poultry.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention provides an immunopotentiator for poultry and application thereof, and belongs to the technical field of biology, the vaccine immunopotentiator for poultry comprises 0.4%-1.0% w / v of echinacea extract and 0.2%-1.0% w / v of vitamin E. The vaccine immunopotentiator is applied to a vaccine composition, can effectively stimulate a body to quickly generate a high-level antibody, and can be used for preparing a vaccine for poultry. In addition, the immune duration is effectively prolonged, and the vaccine use efficiency can be greatly improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of biotechnology, in particular to an immunopotentiator for poultry and application thereof. Background Art

[0002] Avian influenza (AI) is a highly contagious acute respiratory disease caused by avian influenza virus (AIV). AIV is a single-stranded negative-sense segmented RNA virus belonging to the family Orthomyxoviridae and the genus Influenza A. According to the different pathogenicity and virulence of the virus, it can be clinically divided into highly pathogenic avian influenza virus and low pathogenic avian influenza virus. The H5, H7 and H9 subtypes are prevalent in chickens in my country. Due to their strong pathogenicity, the H5 and H7 subtypes can cause large-scale deaths in poultry and have the risk of infecting humans. Therefore, the isolation, identification and vaccine development of H5 and H7 subtype avian influenza viruses are subject to state control. Only research institutes and enterprises with certain qualifications can research and produce vaccines. The H9 subtype is a low pathogenic avian influenza. It will not cause large-scale deaths in the flock after infection, but the infection rate is relatively high, which will lead to a significant drop in egg production. Moreover, since it is easy to synergize with other pathogenic microorganisms, it can cause secondary infections, thereby causing a high mortality rate in poultry flocks, bringing huge economic losses to the breeding industry.

[0003] At present, vaccination is one of the main means of preventing and controlling H9 subtype avian influenza. Although the H9 subtype avian influenza vaccine in the existing technology can produce a certain immune response, it still has the problems of slow immune onset, insufficient immune effect, and immune duration that cannot meet actual needs. Therefore, it is urgent to provide an immune enhancer for poultry in clinical practice, which can stimulate the body to quickly produce antibodies after acting together with an adjuvant, and can ensure a longer immune duration. Summary of the invention

[0004] The first purpose of the present invention is to provide an immunopotentiator for poultry seedlings, which can be used in poultry seedling preparations and work together with adjuvants to stimulate the body to quickly produce high levels of antibodies and effectively prolong the duration of immunity to solve the above-mentioned technical problems.

[0005] The second object of the present invention is to provide an application of an immunopotentiator in poultry vaccines.

[0006] A third object of the present invention is to provide a poultry vaccine comprising the above-mentioned immunopotentiator.

[0007] In order to achieve the above objectives, the following technical solutions are adopted:

[0008] The present invention provides an immunopotentiator, which comprises echinacea extract and vitamin E with a final concentration of 0.4% to 1.0% w / v.

[0009] Preferably, the immunopotentiator comprises Echinacea extract and 1.0% w / v vitamin E in a final concentration of 1.0% w / v in the vaccine.

[0010] Preferably, the immunopotentiator comprises Echinacea extract and vitamin E at a final concentration of 0.7% w / v in the vaccine.

[0011] Preferably, the immunopotentiator comprises 0.5% w / v Echinacea extract and 0.5% w / v vitamin E in the final concentration of the vaccine.

[0012] In the above-mentioned immunopotentiator, the final concentration ratio is a mass-to-volume ratio, which is calculated based on the final concentration of the Echinacea extract and vitamin E in the vaccine composition in which the immunopotentiator is finally located.

[0013] In some technical schemes of the present invention, the preparation method of the Echinacea extract is: using dried Echinacea as raw material, the raw material is crushed and canned, and 70% ethanol-water is used as solvent, after heating and reflux extraction, the ethanol is recovered, heated and concentrated to evaporate the water to obtain an extract, and dried in a spray drying tower to obtain the Echinacea extract powder.

[0014] Preferably, the preparation method of the Echinacea extract is: using dried Echinacea whole herb with flowers as raw material, the raw material is crushed and canned, and 70% ethanol-water is used as solvent, and reflux is heated and extracted three times, each time for 2 hours, the three extracts are combined, and the ethanol is recovered until the extract has no alcohol content, and then heating and concentrating to evaporate water to an extract with a specific gravity of D=1.1, and drying with a spray drying tower to obtain the Echinacea extract powder.

[0015] In some technical solutions of the present invention, the content of Echinacea polyphenols in the Echinacea extract is 4.3% to 4.5% as determined by UV ultraviolet spectroscopy.

[0016] In the above scheme, the mass volume concentration of the Echinacea extract solution is 10% to 20%.

[0017] Furthermore, the preparation method of the Echinacea extract solution is as follows: 10 g to 20 g of the Echinacea extract is dissolved in 100 ml of water for injection, and filtered through a 0.22 μm filter membrane to prepare a 10% to 20% (w / v) solution.

[0018] In the above scheme, the mass volume concentration of the vitamin E solution is 10% to 20%.

[0019] Furthermore, the preparation method of the vitamin E solution is: 10g-20g of vitamin E is dissolved in 100ml of water for injection, filtered through a 0.22μm filter membrane, and prepared into a 10%-20% (w / v) solution.

[0020] The present invention also provides a poultry vaccine composition, which comprises the poultry vaccine antigen and the above-mentioned immunopotentiator.

[0021] Furthermore, the poultry vaccine composition also contains an adjuvant.

[0022] The poultry vaccine antigens are inactivated viruses and subunit antigens.

[0023] The poultry vaccine antigen is one or more of H5 subtype avian influenza virus / subunit antigen, H7 subtype avian influenza virus / subunit antigen, and H9 subtype avian influenza virus / subunit antigen.

[0024] The antigen ratio of the poultry vaccine is 10% to 37%, preferably 20% (V / V).

[0025] The adjuvant can be an oil adjuvant, a water adjuvant, a water-in-oil adjuvant, an oil-in-water adjuvant, an oil-in-water-in-oil adjuvant, or a water-in-oil-in-water adjuvant.

[0026] Preferably, the adjuvant is a white oil adjuvant.

[0027] More preferably, the ratio of the adjuvant is 60% to 70%, preferably 66% (V / V).

[0028] The present invention also provides the use of the above-mentioned immunopotentiator in preparing a vaccine composition for poultry.

[0029] Compared with the prior art, the present invention has the following beneficial effects:

[0030] The immunopotentiator and vaccine composition provided by the present invention can effectively stimulate the body to quickly produce high-level antibodies, and effectively prolong the duration of immunity, which can greatly improve the efficiency of vaccine use. DETAILED DESCRIPTION

[0031] The embodiments of the present invention will be described in detail below in conjunction with the embodiments and examples, but it will be appreciated by those skilled in the art that the following embodiments and examples are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. Based on the embodiments in the present invention, all other embodiments obtained by those of ordinary skill in the art without making creative work are within the scope of protection of the present invention. If specific conditions are not specified, proceed according to normal conditions or conditions recommended by the manufacturer. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be purchased commercially.

[0032] The present invention is further described below by means of specific examples and comparative examples. However, it should be understood that these examples are only used for more detailed description and should not be construed as limiting the present invention in any form.

[0033] Example 1

[0034] 1. Preparation of Echinacea Extract

[0035] The whole dried Echinacea with flowers is used as raw material, the raw material is crushed, canned, and 70% ethanol-water is used as solvent, heated and refluxed for extraction three times, each time for 2 hours, the three extracts are combined, the ethanol is recovered until the extract has no alcohol content, and the water is further heated and concentrated to evaporate the extract to a specific gravity of D=1.1, and the Echinacea extract powder is dried in a spray drying tower. The Echinacea polyphenol content is 4.3% by UV ultraviolet spectrum measurement.

[0036] 2. Preparation of Echinacea Solution

[0037] Take 10 g of Echinacea extract and dissolve it in 100 ml of water for injection, filter it through a 0.22 μm filter membrane, and prepare a 10% (w / v) solution.

[0038] 3. Preparation of Vitamin E Solution

[0039] Take 10 g of vitamin E and dissolve it in 100 ml of water for injection, filter it through a 0.22 μm filter membrane, and prepare a 10% (w / v) solution.

[0040] 4. Preparation of H9 subtype avian influenza virus solution

[0041] Suspension MDCK cells (purchased from ATCC) were inoculated into the bioreactor to a cell density of 1.0×10 6 ~1.3×10 6 / ml. Set the temperature to 37°C, dissolved oxygen (DO) value to 40% to 50%, pH value to 7.0, and culture at an appropriate speed. When the cell density reaches 4.0×10 6 ~6.0×10 6 / ml, inoculate H9 subtype avian influenza virus JS121 strain (deposit number CCTCC NO.V2023102, deposited in China Center for Type Culture Collection, deposit address is Wuhan University, Wuhan, China, deposit date November 12, 2023, classified and named H9 subtype avian influenza virus JS121 strain Avianinfluenza virus H9-JS121) at a ratio of 0.001% to 0.01% (v / v), and add TPCK-trypsin with a final concentration of 5 μg / ml, set the temperature to 33°C, dissolved oxygen to 40% to 50%, and pH to 7.2, and culture at an appropriate speed for 48 to 72 hours. When the suspended cells show death, disintegration, and fragmentation, and the cell density is lower than 2.0×106 The virus solution was harvested when the concentration was 1.5447 / ml.

[0042] The virus fluid was sampled and serially diluted 10-fold using serum-free medium containing TPCK-trypsin at a final concentration of 5 μg / ml. The samples were inoculated into 96-well culture plates with monolayer MDCK cells, 0.1 ml per well, and 5 wells were inoculated for each dilution. Normal cells were also set as controls. The cells were cultured in a 33°C, 5% CO2 incubator for 4 days. Samples were taken from each well to determine the red blood cell agglutination titer. Those with agglutination titer of not less than 1:16 (micro-assay method) were considered infected. The number of infected wells at each dilution was recorded, and TCID50 was calculated according to the Reed-Muench method. The virus content was determined to be 10 11.5 TCID50 / ml.

[0043] 5. Inactivation of H9 subtype avian influenza virus antigens

[0044] Dilute the analytically pure formaldehyde solution 10 times with purified water, add it to the virus solution in the above step, and shake it while adding to make the final concentration 0.1% (V / V). After thorough shaking and mixing, transfer it into another sterile container, seal it and inactivate it at 37℃ for 24 hours, shake it once every 4 to 6 hours, and directly harvest it to obtain the inactivated antigen solution.

[0045] 6. Preparation of vaccine composition

[0046] The inactivated antigen solution of H9 subtype avian influenza virus was emulsified with mineral oil adjuvant according to the immunopotentiators described in the following table to prepare vaccine compositions of different proportions (the final total preparation volume was 100 ml).

[0047] The emulsification method is:

[0048] Preparation of the oil phase: 94 parts of mineral oil and 2 parts of aluminum stearate are mixed evenly and heated to 80°C, and then 6 parts of SIBEN-80 are added until the temperature reaches 121°C and maintained for 40 minutes. After cooling, it is set aside.

[0049] Preparation of aqueous phase: Dilute the inactivated antigen of H9 subtype avian influenza virus with physiological saline to the required virus content according to the antigen content before inactivation, add the prepared Echinacea solution and vitamin E solution, mix well and set aside.

[0050] For emulsification, slowly add 1 part of water phase into 2 parts of oil phase, emulsify at 3600r / min for 40 minutes and then package.

[0051] Table 1. Vaccine composition ratio

[0052]

[0053] Example 2

[0054] The vaccine composition prepared in Example 1 was subjected to immune protection experiments using serological methods and immune challenge methods, and the results are shown in Table 2-3.

[0055] The specific steps of the serological method are as follows: 65 3-week-old SPF chickens were divided into 7 groups, with 10 chickens in each group from the first group to the sixth group, and 5 chickens in the seventh group. Groups 1 to 6 were subcutaneously injected with 0.3 ml of vaccines 1 to 6 prepared according to the method in Example 1 of the H9 subtype avian influenza virus JS121 strain, and group 7 was not immunized as a control. 21 days after vaccination, blood was collected from each chicken, serum was separated, and HI antibody titer was determined according to the method of the current "Chinese Veterinary Pharmacopoeia". The geometric mean of the HI antibody titer of the immune group can reach up to 1:2048 (micro method), and the geometric mean of the HI antibody titer of the non-immunized control group is not higher than 1:2 (micro method). The test results are shown in the table below.

[0056] Table 2. HI antibody titer 21 days after vaccination

[0057]

[0058] Note: “ / ” means there is no content for this item, and “GMT” means geometric mean.

[0059] The test results showed that the serum HI antibody titer of chickens 21 days after immunization with vaccine 1, vaccine 2, vaccine 3, vaccine 4, vaccine 5 and vaccine 6 was much higher than the geometric mean 1:64 (micro-method) vaccine standard; the serum HI antibody titer of the vaccine group containing immunopotentiator (vaccine 1, vaccine 2, vaccine 3, vaccine 4, vaccine 5) of the present invention was 1.3 to 1.7 titers higher than that of the vaccine group not containing immunopotentiator (vaccine 6); the geometric mean of serum HI antibody titer of vaccine 2 and vaccine 3 after immunization was consistent, both of which were 1:2048 (micro-method).

[0060] The specific steps of the immune challenge method are as follows: 65 SPF chickens in the above "1. Serological method" were used. After 21 days of immunization, each chicken was intravenously injected with H9 subtype avian influenza virus JS121 strain virus solution, 0.2 ml / chicken (containing 2×10 6.0 EID50). On the 5th day after the virus attack, the laryngeal and cloacal swabs of each chicken were collected, and 5 10-day-old SPF chicken embryos were inoculated through the allantoic cavity, 0.2 ml per embryo, incubated and observed for 120 hours, and the HA titer of the chicken embryo fluid was determined embryo by embryo. As long as the HA titer of one chicken embryo fluid among the 5 chicken embryos inoculated with each swab sample is not less than 1:16 (micro-dosage method), it can be judged as positive for virus isolation. For samples with negative virus isolation, it should be blindly propagated for one generation before judgment. The results are detailed in the table below.

[0061] Table 3. Positive rate of virus isolation 21 days after vaccination

[0062] Group Virus isolation positive rate Vaccine 1 0 / 10 Vaccine 2 0 / 10 Vaccine 3 0 / 10 Vaccine 4 0 / 10 Vaccine 5 0 / 10 Vaccine 6 0 / 10 Control group 5 / 5

[0063] The results showed that 21 days after chickens were immunized with vaccine 1, vaccine 2, vaccine 3, vaccine 4, vaccine 5 and vaccine 6, the immune efficacy was verified by virus challenge, and no virus was isolated from the larynx and cloaca of all chickens, and the virus isolation rate was 0 / 10. This shows that after immunization with the inactivated avian influenza vaccine containing an immunopotentiator and the inactivated avian influenza vaccine without an immunopotentiator, the chickens did not excrete toxins, and were able to completely resist the infection of H9 subtype avian influenza, with a good immune protection effect.

[0064] Comparative Example 1

[0065] 1. Comparative immunogenicity test 1

[0066] 45 3-week-old SPF chickens were divided into 5 groups, with 10 chickens in each group of the 1st to 4th groups and 5 chickens in the 5th group. The 1st to 4th groups were subcutaneously injected with 0.3 ml of the H9 subtype avian influenza virus JS121 strain inactivated vaccine 1 prepared according to the method in Example 1, as well as Comparative Example 1, Comparative Example 2, and Comparative Example 3, respectively, and the 5th group was not immunized as a control. 21 days after vaccination, each chicken was blooded, serum was separated, and HI antibody titer was determined according to the current "Chinese Veterinary Pharmacopoeia". The geometric mean value of HI antibody titer in the vaccine 1 immunization group can reach 1:1552 (micro method), and the geometric mean value of HI antibody titer in Comparative Example 1, Comparative Example 2, Comparative Example 3 and the non-immunized control group is not higher than 1:2 (micro method), and the test results are shown in the following table.

[0067] Table 4 HI antibody titer 21 days after vaccination

[0068]

[0069] Note: “ / ” means there is no content for this item, and “GMT” means geometric mean.

[0070] The results showed that the serum HI antibody titer of chickens immunized with Vaccine 1 21 days later was much higher than the geometric mean 1:64 (micro-dose method) vaccine standard; there was no HI antibody titer in chickens immunized with the immune enhancer ingredients alone, whether it was Comparative Example 1 containing only Echinacea, Comparative Example 2 containing vitamin E, or Comparative Example 3 containing only Echinacea and vitamin E, 21 days later.

[0071] 2. Comparative immunogenicity test 2

[0072] 45 3-week-old SPF chickens were divided into 5 groups, with 10 chickens in each group of the 1st to 4th groups and 5 chickens in the 5th group. The 1st to 4th groups were subcutaneously injected with 0.3 ml of the inactivated vaccine 1, vaccine 6, vaccine 7 and vaccine 8 of the H9 subtype avian influenza virus JS121 strain prepared according to the method in Example 1, respectively, and the 5th group was not immunized as a control. 21 days after inoculation, each chicken was blooded and serum was separated, and HI antibody titer was determined according to the current "Chinese Veterinary Pharmacopoeia". The geometric mean value of the serum HI antibody titer of the vaccine 1 immunization group on day 21 can reach 1:1552 (micro method), and the geometric mean value of the HI antibody titer of the non-immunized control group is not higher than 1:2 (micro method), and the test results are shown in the table below.

[0073] Table 5 HI antibody titer 21 days after vaccination

[0074]

[0075] Note: “ / ” means there is no content for this item, and “GMT” means geometric mean.

[0076] The results showed that the serum HI antibody titer of chickens 21 days after immunization with vaccine 1, vaccine 6, vaccine 7 and vaccine 8 was much higher than the geometric mean 1:64 (micro-method) vaccine standard; the HI antibody titer of the vaccine group (vaccine 1) containing both echinacea and vitamin E of the present invention was higher than that of the vaccine group not containing immune enhancer (vaccine 6); the HI antibody titer of chickens immunized with vaccine 1 containing both echinacea and vitamin E was 1.2 to 1.3 titers higher than the antibody titer of chickens immunized with vaccine 7 containing only echinacea or vaccine 8 containing only vitamin E; this indicates that the combined use of echinacea and vitamin E has a synergistic effect in the immune response.

[0077] 3. Comparative test of duration of immunity

[0078] 45 3-week-old SPF chickens were divided into 5 groups, with 10 chickens in each group from group 1 to group 4 and 5 chickens in group 5. Groups 1 to 4 were subcutaneously injected with 0.3 ml of inactivated vaccine 1, vaccine 4, vaccine 5 and vaccine 6 of H9 subtype avian influenza virus JS121 strain prepared according to the method in Example 1, respectively, and group 5 was not immunized as a control. At 3 weeks, 8 weeks, 12 weeks, 20 weeks and 28 weeks after vaccination, blood was collected from each chicken, serum was separated, and HI antibody titer was determined according to the current "Chinese Veterinary Pharmacopoeia". The test results are shown in the table below.

[0079] Table 6 HI antibody titers at different times after vaccination

[0080]

[0081] The results showed that the serum HI antibody titers of chickens immunized with Vaccine 1, Vaccine 4 and Vaccine 5 containing both Echinacea and vitamin E at 3, 8, 12, 20 and 28 weeks were higher than the serum antibody levels of chickens immunized with Vaccine 6 without the immunopotentiator at 3 weeks, 8 weeks, 12 weeks, 20 weeks and 28 weeks after the chickens were immunized; Vaccine 1, Vaccine 4 and Vaccine 5 containing the immunopotentiator still maintained a relatively high antibody level 28 weeks after the chickens were immunized, which was much higher than the antibody titers of chickens immunized with Vaccine 6 without the immunopotentiator; Vaccine 1, Vaccine 4 and Vaccine 5 containing the immunopotentiator ... at the same time containing the minimum amount of Echinacea extract and vitamin E, and Vaccine 1, Vaccine 4 and Vaccine 5 containing the minimum amount of Echinacea extract and vitamin E, respectively. There was no significant difference in serum HI antibody titers at 3, 8, 12, 20 and 28 weeks after immunization of chickens with Vaccine 4 with the highest amount of added vitamin E and Vaccine 5 with the highest amount of added echinacea and the lowest amount of added microorganism E. Compared with Vaccine 6 without immune enhancer, there was no significant difference in serum HI antibody titers at 3, 8, 12, 20 and 28 weeks after immunization of chickens with Vaccine 7 containing only Echinacea and the highest amount of added vitamin E and Vaccine 8 containing only vitamin E and the highest amount of added vitamin E, and all of them were lower than the HI antibody levels of chickens after immunization with Vaccine 1, Vaccine 4 and Vaccine 5.

[0082] Effect example

[0083] Vaccine compositions with different concentrations of Echinacea and vitamin E extracts and final concentration ratios were prepared according to Table 7 below, and serological experiments were performed on the prepared vaccines to detect the serum HI antibody titer of chickens immunized 21 days later. The results are shown in Table 8.

[0084] Table 7 Vaccine compositions at different concentration ratios

[0085]

[0086] Table 8 HI antibody titer test results of different vaccine compositions

[0087]

[0088] The results showed that when the concentration of the echinacea extract solution (W / V) and the vitamin solution (W / V) in the present invention was 10% to 20%, it did not affect the immune enhancement effect after being added to the vaccine. The average serum HI antibody titers of vaccines 11, 12, and 13, in which the final concentrations of echinacea and vitamin E added in the vaccine were both 1%, were 11.0 21 days after immunization of chickens, which were 0.4 to 0.5 titers better than the antibody titers of vaccines 9 and 10 after immunization of chickens.

[0089] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. An immune enhancer, It is characterized in that The echinacea extract and vitamin E in the final concentration of 0.4% to 1.0% w / v are contained therein.

2. The immunopotentiator according to claim 1, It is characterized in that It contains Echinacea extract and vitamin E at a final concentration of 1.0% w / v; Preferably, the composition comprises Echinacea purpurea extract and vitamin E at a final concentration of 0.7% w / v; Preferably, the final concentration of the echinacea extract and the vitamin E are 0.5% w / v.

3. The immunopotentiator according to claim 1 or 2, It is characterized in that The preparation method of the Echinacea extract is: The dried Echinacea is used as raw material, the raw material is crushed, canned, and 70% ethanol-water is used as solvent. After heating and reflux extraction, the ethanol is recovered, heated and concentrated to evaporate water to obtain an extract, and the Echinacea extract powder is dried in a spray drying tower. Preferably, the preparation method of the Echinacea extract is: The whole dried Echinacea purpurea with flowers is used as raw material, the raw material is crushed and canned, and 70% ethanol-water is used as solvent, and the extraction is heated and refluxed for three times, each time for 2 hours, the three extracts are combined, and the ethanol is recovered until the extract has no alcohol content, and the water is further heated and concentrated to evaporate the extract to a specific gravity of D=1.1, and the Echinacea purpurea extract powder is obtained by drying in a spray drying tower.

4. The immunopotentiator according to claim 3, It is characterized in that The content of Echinacea polyphenols in the Echinacea extract is 4.3% to 4.5%.

5. The immunopotentiator according to claim 1 or 2, It is characterized in that The mass volume concentration of the Echinacea extract solution is 10% to 20%; Preferably, the preparation method of the Echinacea extract solution is as follows: 10 g to 20 g of the Echinacea extract is dissolved in 100 ml of water for injection, and filtered through a 0.22 μm filter membrane to prepare a 10% to 20% (w / v) solution.

6. The immunopotentiator according to claim 1 or 2, It is characterized in that The mass volume concentration of the vitamin E solution is 10% to 20%. Preferably, the preparation method of the vitamin E solution is: 10g-20g of vitamin E is dissolved in 100ml of water for injection, and filtered through a 0.22μm filter membrane to prepare a 10%-20% (w / v) solution.

7. A poultry vaccine composition comprising a poultry vaccine antigen and the immunopotentiator according to any one of claims 1 to 6; Preferably, the poultry vaccine composition further comprises an adjuvant.

8. The poultry vaccine composition according to claim 7, It is characterized in that The poultry vaccine antigens are inactivated viruses and subunit antigens; Preferably, the poultry vaccine antigen is one or more of H5 subtype avian influenza virus / subunit antigen, H7 subtype avian influenza virus / subunit antigen, and H9 subtype avian influenza virus / subunit antigen.

9. The poultry vaccine composition according to claim 7, It is characterized in that The adjuvant is an oil adjuvant, a water adjuvant, a water-in-oil adjuvant, an oil-in-water adjuvant, an oil-in-water-in-oil adjuvant, or a water-in-oil-in-water adjuvant; Preferably, the adjuvant is a white oil adjuvant.

10. The poultry vaccine composition according to claim 7, It is characterized in that The adjuvant is used in an amount of 60% to 70%, preferably 66% (V / V); More preferably, the ratio of the poultry vaccine antigen is 10% to 37%, and further preferably 20% (V / V).